Where one study disagrees with what other studies report for the same models, and what we are doing to resolve each case.
These are automatic leads, not findings of error. Each release, a check compares how every study ranks the models it shares with other studies. It flags a study that reverses the order the others agree on, or whose gap to a shared reference model lies well outside theirs. Different tasks, populations or metrics often explain a flag.
A flag never hides a result. Flagged results stay in every table, page and download, marked Contested. A result is withheld only when a reviewer marks it disputed.
Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks REVEL above ClinPred in 6 of 7 comparisons; 2 of 2 other studies rank ClinPred above REVEL.
3 papers rank ClinPred above REVEL in 10 of their 12 comparisons and REVEL higher in 1; 1 is a tie. Livesey and Marsh 2025 ranks REVEL above ClinPred in 6 of its 7 comparisons and ClinPred higher in 1.
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes ranks MVP above REVEL in 4 of 5 comparisons; 3 of 3 other studies rank REVEL above MVP.
3 papers rank REVEL above MVP in all 19 comparisons that are not ties (4 are ties). Clinical likelihood ratios and balanced… ranks MVP above REVEL in 4 of its 5 comparisons and REVEL higher in 1.
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks BayesDel above REVEL in 6 of 6 comparisons; 2 of 2 other studies rank REVEL above BayesDel.
3 papers rank REVEL above BayesDel in 11 of their 14 comparisons and BayesDel higher in 2; 1 is a tie. Of those papers, ProteinGym ranks BayesDel higher on its own (1 of 1). An openly licensed benchmark… ranks BayesDel above REVEL in all 6 of its comparisons.
Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above REVEL in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks REVEL above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.
2 papers rank MutFormer above REVEL in 6 of their 13 comparisons and REVEL higher in 7. Of those papers, An openly licensed benchmark… ranks REVEL higher on its own (6 of 6).
Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks REVEL above MutScore in 6 of 6 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutScore above REVEL in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.
2 papers rank MutScore above REVEL in 6 of their 13 comparisons and REVEL higher in 6; 1 is a tie. Of those papers, Livesey and Marsh 2025 ranks REVEL higher on its own (6 of 7).